BIOG.LSE The Biotech Growth Trust PLC
- Market cap
- GBX 250M
- P/E
- 2.4x
- P/B
- 0.90x
- ROE
- 46.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Mar 2026.
Is BIOG.LSE undervalued?
Graham numberThe Graham number of The Biotech Growth Trust PLC cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
The Biotech Growth Trust PLC fundamental analysis
No fundamental analysis for The Biotech Growth Trust PLC yet.
The Biotech Growth Trust PLC stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About The Biotech Growth Trust PLC
The Biotech Growth Trust PLC is a closed ended equity mutual fund launched by Frostrow Capital LLP. It is co-managed by OrbiMed Capital LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the biotechnology sector. The fund invests in stocks of companies across all market capitalizations. It employs fundamental analysis to create its portfolio. The fund benchmarks the performance of its portfolio against the …
Full company profileThe Biotech Growth Trust PLC financial statements
The Biotech Growth Trust PLC annual financial statements (GBP; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 100M | -27.5M | 23.0M | 63.9M | 204M | -210M | -37.7M | 80.3M | -77.5M | 137M |
| Gross Profit | 96.4M | -31.9M | 29.0M | 68.9M | 222M | -215M | -43.0M | 78.0M | -78.8M | 133M |
| Operating Income | 98.9M | -29.1M | 24.5M | 64.7M | 197M | -200M | -36.7M | 76.5M | -82.5M | 132M |
| EBITDA | 101M | 2.39M | 21.3M | 64.7M | 197M | -10.7M | -5.34M | 75.9M | -82.5M | 131M |
| Net Income | 98.3M | -29.8M | 21.1M | 60.9M | 200M | -202M | -41.3M | 74.6M | -82.7M | 130M |
| EPS | 1.72 | -0.53 | 0.39 | 1.35 | 5.00 | -4.88 | -1.03 | 2.07 | -2.62 | 5.58 |
| Balance Sheet | ||||||||||
| Total Assets | 461M | 446M | 431M | 401M | 650M | 427M | 361M | 411M | 227M | 302M |
| Total Liabilities | 13.1M | 28.7M | 22.4M | 35.6M | 48.1M | 33.2M | 30.2M | 50.1M | 5.42M | 20.3M |
| Shareholders' Equity | 447M | 417M | 409M | 366M | 601M | 394M | 330M | 361M | 221M | 282M |
| Cash & Short-term Investments | - | - | - | 0.00 | 1.50M | 1.50M | 2.77M | 2.13M | 8.45M | 0.00 |
| Total Debt | 13.1M | 22.1M | 10.8M | 32.7M | 26.8M | 31.7M | 20.2M | 47.1M | - | 12.3M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -5.29M | -4.11M | -4.40M | -3.77M | -5.67M | -12.1M | -5.89M | -4.24M | -5.09M | -5.98M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.05M | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -5.29M | -4.11M | -4.40M | -3.77M | -5.67M | -13.2M | -5.89M | -4.24M | -5.09M | -5.98M |
| Ratios | ||||||||||
| ROE | 22.0% | -7.1% | 5.2% | 16.7% | 33.3% | -51.3% | -12.5% | 20.6% | -37.4% | 46.2% |
| ROA | 21.3% | -6.7% | 4.9% | 15.2% | 30.9% | -47.4% | -11.5% | 18.1% | -36.5% | 43.1% |
| Net Profit Margin | 97.8% | - | 91.6% | 95.3% | 98.1% | - | - | 92.8% | - | 95.0% |
| Debt to Equity | 0.03x | 0.05x | 0.03x | 0.09x | 0.04x | 0.08x | 0.06x | 0.13x | - | 0.04x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
The Biotech Growth Trust PLC dividends
The Biotech Growth Trust PLC has not paid dividends in the last 10 fiscal years.
Who owns The Biotech Growth Trust PLC
- Insiders 0.58%
- Institutions 30.64%
- Public & others 68.79%
- Shares outstanding 18.4M
- Free float 10.4M
The Biotech Growth Trust PLC company profile
- Company name
- The Biotech Growth Trust PLC
- Ticker
- BIOG.LSE
- ISIN
- GB0000385517
- Exchange
- London Exchange
- Sector
- Financial Services
- Industry
- Capital Markets
- Fiscal year end
- March
- Address
- 601 Lexington Avenue, New York, NY, United States, 10022
- Phone
- 212 739 6400
About The Biotech Growth Trust PLC
The Biotech Growth Trust PLC is a closed ended equity mutual fund launched by Frostrow Capital LLP. It is co-managed by OrbiMed Capital LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the biotechnology sector. The fund invests in stocks of companies across all market capitalizations. It employs fundamental analysis to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotechnology Index. It was previously known as Finsbury Emerging Biotechnology Trust PLC. The Biotech Growth Trust PLC was formed on May 20, 1997 and is domiciled in the United Kingdom.
The Biotech Growth Trust PLC management
1- Mr. Samuel David IsalyPortfolio Manager · born 1945